摘要: Glucagon-like peptide 1 receptor (GLP1R) agonists are an important class of antidiabetic drugs with an attractive clinical profile – including improved glycemic control, weight loss, and decreased risk of major adver...
[5] Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial[J]. Di...
[15]. Brunton S. J Fam Pract. 2016 Apr;65(4 Suppl):supp_az_0416. [16]. https://ecuadoctors.com/oral-anti-diabetic-drugs-classification/ ADA. Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. [17]. Lingvay I, et al. JAMA. 2016 Mar 1;315(9):898-907. [18]. Aroda VR, et...
DREADD:经过基因工程改造设计的受体只对配体药物敏感(Designer Receptors Exclusively Activated by Designer Drugs)。 hM3Dq:当 CNO 结合到 hM3Dq 受体上时,它会激活 Gq 蛋白介导的钙动员,进一步引发一系列下游效应,如增强神经元的兴奋性[6]。 hM4Di:当 CNO 与 hM4Di 结合时,它会激活 Gi 蛋白对 cAMP(环磷...
8. HARRIS S B, KOCSIS G, PRAGER R, et al. Safety and efficacy of IdegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab, 2017, 19(6): 858-65. ...
24. Jendle J, et al. Expert Opin Investig Drugs. 2012; 21(10): 1463-1474. 25. 德谷胰岛素利拉鲁肽注射液说明书(2021年10月26日). 26. Kapitza C, et al. J Clin Pharmacol. 2015; 55(12): 1369-1377. 27. Billings LK, et al. Diabetes Care. 2018; 41(5): 1009-1016. ...
8. HARRIS S B, KOCSIS G, PRAGER R, et al. Safety and efficacy of IdegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab, 2017, 19(6): 858-65. ...
9.Rybelsus. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/ 209637s003lbl.pdf Accessed October 21, 2019. 10.Bucheit JD, et al. Diabetes Technol Ther.2020;22(1):10-18. 撰写:安墨 审核:Nia 执行:Atai...
[4] Mima A, Nomura A, Fujii T. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review. Biomed Pharmacother. 2023;165:115032. [5]Cao Y, Cao S, Zhao J, Zhao J, Zhao Y and Liu Y (2024) Efficacy and safety of polyethylene glycol loxe...
5.Xiaohui Guo et al.Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial Diabetes...